CyFlow IgD Purified (RUO)
| 品番 | AZ280259 | ||
|---|---|---|---|
| 抗体名 | Anti-Hu IGD PURI,IA6-2 | ||
| 包装単位 | 0.1 mg | ||
| 濃度 | 1 mg/ml | ||
| 推奨使用量 | - | ||
| 容量 | 0.1 ml | ||
| 関連製品 (アイソタイプコントロール) |
Mouse IgG2a Purified (CJ747338) Mouse IgG2a Purified (AP005692) |
||
| 反応性|交差吸着 | Human | レーザー | - |
| 抗原 | IgD | 最大蛍光波長 | - |
| クローン | IA6-2 | 最大励起波長 | - |
| ホスト | Mouse | 標識/Format | Purified |
| アイソタイプ | IgG2a | 研究分野 | Immunophenotyping | Immunoglobulins |
| クローナリティ | monoclonal | アプリケーション | - |
Anti-Hu IGD PURI,IA6-2
特異性
The mouse monoclonal antibody IA6-2 recognizes human immunoglobulin D (IgD).
抗原情報
Immunoglobulin D (IgD) is expressed on the surface of naive mature B cells, thus later than IgM, and is coexpressed with it then. Triggered by antigen binding, it signals through the CD79 complex to activate the B cells. Expression of IgD is lost after the isotype switch. Soluble IgD is present in very small amounts in the serum. IgD can bind to basophils and mast cells to activate them in an IgE-independent way to participate in respiratory immune defense.
利用方法
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Baier G, Baier-Bitterlich G, Looney DJ, Altman A: Immunogenic targeting of recombinant peptide vaccines to human antigen‑presenting cells by chimeric anti‑HLA‑DR and anti‑surface immunoglobulin D antibody Fab fragments in vitro. J·Virol. 1995·Apr; 69(4):2357‑65. <·PMID:·7533857·>
• Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, Hogan SL, Poulton CJ, Berg EA, Falk RJ, Nachman PH: Decreased CD5+ B cells in active ANCA vasculitis and relapse after rituximab. Clin·J·Am·Soc·Nephrol. 2013·Mar; 8(3):382‑91. <·PMID:·23293123·>
• Chang NH, McKenzie T, Bonventi G, Landolt-Marticorena C, Fortin PR, Gladman D, Urowitz M, Wither JE: Expanded population of activated antigen‑engaged cells within the naive B cell compartment of patients with systemic lupus erythematosus. J·Immunol. 2008·Jan·15; 180(2):1276‑84. <·PMID:·18178868·>
• Degauque N, Ngono AE, Akl A, Lepetit M, Crochette R, Giral M, Lepourry J, Pallier A, Castagnet S, Dugast E, Guillot-Gueguen C, Jacq-Foucher M, Saulquin X, Cesbron A, Laplaud D, Nicot A, Brouard S, Soulillou JP: Characterization of antigen‑specific B cells using nominal antigen‑coated flow‑beads. PLoS·One. 2013·Dec·30; 8(12):e84273. <·PMID:·24386360·>
• Di Sabatino A1, Carsetti R, Rosado MM, Ciccocioppo R, Cazzola P, Morera R, Tinozzi FP, Tinozzi S, Corazza GR: Immunoglobulin M memory B cell decrease in inflammatory bowel disease. Eur·Rev·Med·Pharmacol·Sci. 2004·Sep-Oct; 8(5):199‑203. <·PMID:·15638230·>
• Ferrari S, Giliani S, Insalaco A, Al-Ghonaium A, Soresina AR, Loubser M, Avanzini MA, Marconi M, Badolato R, Ugazio AG, Levy Y, Catalan N, Durandy A, Tbakhi A, Notarangelo LD, Plebani A: Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc·Natl·Acad·Sci·USA. 2001·Oct·23; 98(22):12614‑9. <·PMID:·11675497·>
• Pugh-Bernard AE, Silverman GJ, Cappione AJ, Villano ME, Ryan DH, Insel RA, Sanz I: Regulation of inherently autoreactive VH4‑34 B cells in the maintenance of human B cell tolerance. J·Clin·Invest. 2001·Oct; 108(7):1061‑70. <·PMID:·11581307·>